RegulatoryCompany release

DBV files FDA application for Viaskin Peanut Patch in children aged 4-7, seeks priority review

🇺🇸 DBV Technologies S.A. (DBVT) · Wed 28 Oct 2026

DBV Technologies says it submitted its Biologics License Application on 29 September, with an FDA filing and priority-review decision expected in the fourth quarter of 2026.

DBV Technologies reported its third-quarter 2026 results on 28 October and confirmed that it submitted a Biologics License Application (BLA) to the US Food and Drug Administration on 29 September. The application covers the Viaskin Peanut Patch in children aged 4 to 7 with peanut allergy, and the company has asked for Priority Review.

The submission rests on the Phase 3 VITESSE trial, which enrolled 654 children. DBV expects the FDA to decide on filing acceptance and on whether to grant priority review in the fourth quarter of 2026. The company reported a third-quarter net loss of $64.5 million.

DBV also said remediation is continuing at Fareva Amboise, its contract manufacturer, following an FDA Warning Letter issued in April 2026. The company did not detail in the material available what the remediation involves or how it may bear on the review of the BLA.

Looking further ahead, DBV expects to file a separate BLA for toddlers aged 1 to 3 in 2027, and says it may submit that application on a rolling basis. For context, a rolling submission allows a sponsor to send completed sections of an application to the FDA as they become ready, rather than all at once.

What it means for your team

  • The FDA's filing and priority-review decision, expected in Q4 2026, is the next regulatory milestone for the 4-7 age group.
  • Quality and CMC teams should note that the manufacturing site's April 2026 Warning Letter remains under remediation while the BLA is under consideration.
  • Market-access planners can treat 2027 as the expected timeframe for a toddler (1-3) filing, possibly on a rolling basis, which would widen the eligible population later.

Company's press release (SEC filing): DBV Technologies S.A. ↗

Article written by VigiEye from the official source (DBV Technologies S.A.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →